logo-loader
viewCircassia Pharmaceuticals PLC

Circassia Pharmaceuticals plots a path to profitability

Snapshot

  • Specialty pharma group focused on respiratory diseases
  • Growing revenue base; set its sights on profitability
  • New product launch will be pivotal to those aspirations
Circassia Pharmaceuticals PLC -

Quick facts: Circassia Pharmaceuticals PLC

Price: 25.1 GBX

LSE:CIR
Market: LSE
Market Cap: £94.18 m
Follow

 

 

What it does

Circassia Pharmaceuticals PLC (LON:CIR) is a specialty pharma company focused on treating patients with respiratory diseases.

It currently markets two products: NIOX, which is used to help manage asthma, and Tudorza, a chronic obstructive pulmonary disease (COPD) treatment. 

Duaklir, also used to treat COPD, was launched in the US in October, marking a "major strategic milestone".

It is a long-acting therapy that comes in powder form and is administered using an inhaler.

Tudorza and Duaklir have both been in-licensed from FTSE 100 giant AstraZeneca PLC (LON:AZN).

It has several other asthma and COPD treatments in its pipeline, as well as AirNOvent – a portable system that uses electricity to make nitric oxide, which is used to dilate blood vessels in the lungs.

So, how’s Circassia doing?

In short, not bad. Its interim results set the road-map to profitability as it reported strong growth in first-half sales alongside a reduction in costs and cash outflows.

Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the figure set to more than double to £60-£65mln for the full-year.

In January 2020, the company reported sales in 2019 were in the middle of its guidance of £60-65mln while cash at the year-end was higher than expected at £27mln.

Sales in the middle of the range represent an annual increase of about 31% and include a modest contribution from Duaklir. 

Timing of inventory and rebate payments boosted the cash position, but even without these there was a significant improvement in net cash flow in the second half said the AIM-listed group.

Inflection points

  • The recent launch of Duaklir, which broker Numis in its last note described as a “the key catalyst” for the company.
  • The potential market for the drug is expected to grow to US$1.5bn in the next five years from US$1bn currently.
  • Annual turnover of £75mln would result in the group turning an underlying profit (EBITDA)

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

RNS

Holding(s) in Company

1 day, 19 hours ago

Holding(s) in Company

3 days, 21 hours ago

Holding(s) in Company

5 days, 20 hours ago

Holding(s) in Company

1 week, 2 days ago

Holding(s) in Company

1 week, 2 days ago

Holding(s) in Company

1 week, 3 days ago

2 min read